Tisdag 13 Maj | 15:06:12 Europe / Stockholm

Bifogade filer

Kalender

Est. tid*
2025-11-14 08:00 Kvartalsrapport 2025-Q3
2025-08-29 08:00 Kvartalsrapport 2025-Q2
2025-05-16 N/A X-dag ordinarie utdelning KDEV 0.00 SEK
2025-05-15 N/A Årsstämma
2025-04-30 - Kvartalsrapport 2025-Q1
2025-02-14 - Bokslutskommuniké 2024
2024-11-15 - Kvartalsrapport 2024-Q3
2024-08-30 - Kvartalsrapport 2024-Q2
2024-05-17 - X-dag ordinarie utdelning KDEV 0.00 SEK
2024-05-16 - Årsstämma
2024-04-26 - Kvartalsrapport 2024-Q1
2024-02-16 - Bokslutskommuniké 2023
2023-11-17 - Kvartalsrapport 2023-Q3
2023-08-25 - Kvartalsrapport 2023-Q2
2023-05-17 - X-dag ordinarie utdelning KDEV 0.00 SEK
2023-05-16 - Årsstämma
2023-04-28 - Kvartalsrapport 2023-Q1
2023-02-17 - Bokslutskommuniké 2022
2022-11-18 - Kvartalsrapport 2022-Q3
2022-08-19 - Kvartalsrapport 2022-Q2
2022-05-13 - X-dag ordinarie utdelning KDEV 0.00 SEK
2022-05-12 - Årsstämma
2022-04-29 - Kvartalsrapport 2022-Q1
2022-02-25 - Bokslutskommuniké 2021
2022-01-12 - Extra Bolagsstämma 2022
2021-11-18 - Kvartalsrapport 2021-Q3
2021-08-19 - Kvartalsrapport 2021-Q2
2021-05-06 - X-dag ordinarie utdelning KDEV 0.00 SEK
2021-05-05 - Årsstämma
2021-04-29 - Kvartalsrapport 2021-Q1
2021-02-19 - Extra Bolagsstämma 2021
2021-02-11 - Bokslutskommuniké 2020
2020-11-11 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-06-16 - X-dag ordinarie utdelning KDEV 0.00 SEK
2020-06-15 - Årsstämma
2020-04-30 - Kvartalsrapport 2020-Q1
2020-02-13 - Bokslutskommuniké 2019
2019-11-29 - Kvartalsrapport 2019-Q3
2019-08-30 - Kvartalsrapport 2019-Q2
2019-06-28 - Årsstämma
2019-05-21 - Kvartalsrapport 2019-Q1
2019-05-08 - X-dag ordinarie utdelning KDEV 0.00 SEK
2019-02-14 - Bokslutskommuniké 2018
2018-10-31 - Kvartalsrapport 2018-Q3
2018-08-16 - Kvartalsrapport 2018-Q2
2018-04-27 - X-dag ordinarie utdelning KDEV 0.00 SEK
2018-04-26 - Årsstämma
2018-04-25 - Kvartalsrapport 2018-Q1
2018-02-15 - Bokslutskommuniké 2017
2017-10-31 - Kvartalsrapport 2017-Q3
2017-08-29 - Kvartalsrapport 2017-Q2
2017-05-26 - X-dag ordinarie utdelning KDEV 0.00 SEK
2017-05-24 - Årsstämma
2017-05-16 - Kvartalsrapport 2017-Q1
2017-02-28 - Bokslutskommuniké 2016
2016-11-23 - Kvartalsrapport 2016-Q3
2016-08-31 - Kvartalsrapport 2016-Q2
2016-05-26 - X-dag ordinarie utdelning KDEV 0.00 SEK
2016-05-25 - Årsstämma
2016-05-10 - Kvartalsrapport 2016-Q1
2016-02-23 - Bokslutskommuniké 2015
2015-11-17 - Kvartalsrapport 2015-Q3
2015-08-26 - Kvartalsrapport 2015-Q2
2015-05-21 - X-dag ordinarie utdelning KDEV 0.00 SEK
2015-05-20 - Årsstämma
2015-05-06 - Kvartalsrapport 2015-Q1
2015-02-18 - Bokslutskommuniké 2014
2014-12-04 - Extra Bolagsstämma 2014
2014-10-21 - Analytiker möte 2014
2014-10-21 - Kapitalmarknadsdag 2014
2014-10-21 - Kvartalsrapport 2014-Q3
2014-08-21 - Kvartalsrapport 2014-Q2
2014-05-15 - X-dag ordinarie utdelning KDEV 0.00 SEK
2014-05-14 - Årsstämma
2014-05-08 - Kvartalsrapport 2014-Q1
2014-02-19 - Bokslutskommuniké 2013
2013-11-21 - Analytiker möte 2013
2013-11-21 - Kvartalsrapport 2013-Q3
2013-08-22 - Kvartalsrapport 2013-Q2
2013-05-15 - X-dag ordinarie utdelning KDEV 0.00 SEK
2013-05-14 - Årsstämma
2013-05-10 - Kvartalsrapport 2013-Q1
2013-03-20 - Extra Bolagsstämma 2013
2013-03-20 - Bokslutskommuniké 2012
2013-03-13 - 15-7 2013
2012-11-22 - Analytiker möte 2012
2012-11-22 - Kvartalsrapport 2012-Q3
2012-08-23 - Kvartalsrapport 2012-Q2
2012-05-24 - X-dag ordinarie utdelning KDEV 0.00 SEK
2012-05-23 - Årsstämma
2012-05-15 - Kvartalsrapport 2012-Q1
2012-02-22 - Bokslutskommuniké 2011
2011-11-29 - 15-7 2011
2011-11-25 - Kvartalsrapport 2011-Q3

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorFinans
IndustriInvesteringar
Karolinska Development är verksamt inom investeringsbranschen och fokuserar på långsiktiga ägarinvesteringar i bioteknik- och läkemedelsföretag. Bolagets mål är att utveckla lovande medicinska innovationer sprungna ur akademisk forskning från Karolinska Institutet och andra universitet i Norden. Bolagets portfölj inkluderar företag inom sektorer som bioteknik och medicinteknik. Karolinska Development grundades 2003 och har sitt huvudkontor i Solna.
2022-04-29 09:00:00

STOCKHOLM, Sweden, April 29 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Promimic’s stock starts trading today at Nasdaq First North Growth Market. The shares will be traded under the short name “PRO”.

Prior to the listing on Nasdaq First North Growth Market, Promimic has implemented an ownership spread of the company's shares through a new issue of 5,000,000 shares, which gave the company SEK 80 million before deduction of issue costs. The issue was aimed at institutional investors and the general public in Sweden and was subscribed to 100 percent.

“As the main owner of Promimic, we have supported the company in its ambition to carry out an IPO despite the challenging listing climate. The reason is that both we and Promimic's financial advisers believe that the company's position and growth strategy are strong enough to withstand volatility in the capital market. Our assessment has now proved to be correct – the issue in connection with the listing was fully subscribed, completely without guarantees. The capital injection means that Promimic can boost its sales and marketing activities significantly in the US market, which is of great importance to the company,” says Johan Dighed, General Counsel and Deputy CEO of Karolinska Development.

Karolinska Development's shareholding in Promimic, including indirect ownership by KDev Investments, amounts, after the IPO, to 16.3 percent (1.8 and 14.5 percent, respectively).

For further information, please contact:

Johan Dighed, General Counsel and Deputy CEO, Karolinska Development AB
Phone: +46 70 207 48 26, e-mail: johan.dighed@karolinskadevelopment.com

TO THE EDITORS

About Promimic

Promimic is a growth company that manufactures, markets, and sells biomaterials for improved osseointegration (bone healing) to leading companies in the markets for orthopedic and dental implants. The company has its origins in research at Chalmers University of Technology and today has its head office in Mölndal, Sweden, and a sales office in the US. To date, more than 600,000 operations with implants using the Company's technology have been carried out around the world.

About Karolinska Development AB

Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has a portfolio of nine companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.

For more information, please visit www.karolinskadevelopment.com.